Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with protracted progression-free survival: • Data suggests a link with cancer grade, disease control, and progression-free-survival in patients treated with Bria-IMT™. • Highest rate of disease control and …
• Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May 17-21. • Pathological data of Bria-IMT and its potential link with disease control …
BERKELEY, Calif. and VANCOUVER, British Columbia, February 26, 2021— BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today closed its previously announced underwritten public offering in the United States. The Company offered 4,852,353 common units at a public offering price …
BERKELEY, Calif. and VANCOUVER, British Columbia, February 23, 2021— BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced the pricing of an underwritten public offering in the United States of 5,882,353 units, each unit consisting of one share of …
Clinical and pathological findings presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Median overall survival of 12.5 months in patients with moderately-well differentiated tumors despite an average of 7 failed prior therapy regimens (versus 7.2-9.8 months of others). • Prolonged survival rates and …
• Clinical and pathological data from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the Keystone Symposia, Jan. 25-27, 2021. BERKELEY, Calif. and VANCOUVER, British Columbia, January 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), …
Disease control and survival data is presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Maximum tumor reduction and clinical benefit was observed in heavily pre-treated advanced breast cancer patients, particularly with moderately-well differentiated tumors. • Patients with moderately-well differentiated tumors had a higher …
BERKELEY, Calif., and VANCOUVER, British Columbia, Dec. 1, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously …
BERKELEY, Calif., and VANCOUVER, British Columbia, November 17, 2020 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has closed a brokered private placement (the “Offering”) of an unsecured convertible debenture unit of the Company (the …
• BriaCell and National Cancer Institute to collaborate on Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy, as a treatment for cancer. BERKELEY, Calif., and VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to …